ImmunityBio (IBRX) Short-term Investments (2015 - 2026)

ImmunityBio (IBRX) has 12 years of Short-term Investments data on file, last reported at $175.7 million in Q1 2026.

• On a quarterly basis, Short-term Investments rose 18770.57% year-over-year to $175.7 million in Q1 2026; TTM through Mar 2026 was $175.7 million, a 18770.57% increase from a year earlier, with the FY2025 full-year figure at $154.5 million, up 2321.0% from the prior year.
• Short-term Investments for Q1 2026 stood at $175.7 million, up from $154.5 million in the prior quarter.
• Over the last five years, Short-term Investments for IBRX reached as high as $197.6 million in Q3 2025 and fell as low as $931000.0 in Q1 2025.
• Historically, Short-term Investments has averaged $52.9 million across 5 years, with a median of $16.0 million in 2025.
• Across the five-year window, Short-term Investments plunged 98.21% in 2023 and soared 18770.57% in 2026, its largest moves.
• Year by year, Short-term Investments stood at $2.5 million in 2022, then plunged by 60.32% to $1.0 million in 2023, then jumped by 532.41% to $6.4 million in 2024, then jumped by 2321.0% to $154.5 million in 2025, then grew by 13.72% to $175.7 million in 2026.
• Per Business Quant data, the three most recent Short-term Investments figures were $175.7 million in Q1 2026, $154.5 million in Q4 2025, and $197.6 million in Q3 2025.